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Abstract
Aid for fighting infectious and parasitic diseases has had a statistically
significant role in the under-five mortality reduction in the last decade.
Point estimates indicate a country average reduction of 1.4 deaths per
thousand under fives live-born attributable to aid at its average level in
2000-2010. The effect would be an average drop of 3.3 in the under-five
mortality rate at the aid levels of 2010. By components, a dollar per
capita spent in fighting malaria has caused the largest average impact,
statistically higher than a dollar per capita spent in STD/HIV control.
We do not find statistically significant effects of other infectious disease
aid, including aid for the control of tuberculosis.
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1 Introduction
According to the WHO, 8.3 million children under five died in 2008, down from
10.5 million in 2002.1 That represents a 20.5% reduction in the under five
mortality rate worldwide. The death toll for the group of causes that includes
∗We acknowledge financial support from the Spanish Ministry of Science and Innovation
(Burguet, grant ECO2011-25293; Soto, grant ECO2011-28348).
1We use the figures available from the WHO at http://apps.who.int/ghodata/?vid=10012
(consulted February 22, 2012) since they enable comparison with estimates in 2002 and
2008 using the same methodology. Alternatively, more inclusive estimates for 2008 can be
found in Black et al. (2010), and for the 1990-2007 period, in Ravishankar et al. (2009).
The declining tendency has continued: WHO estimates for 2012 are now at 7.6 million for
2010 (see http://www.who.int/mediacentre/factsheets/fs178/en/index.html, consulted Feb-
ruary 22, 2012)
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only communicable, perinatal, and nutritional conditions, which represent close
to 90% of all under five deaths, decreased by approximately the same percentage.
However, a significantly higher reduction has occurred in the number of deaths
attributed to a small subgroup of these causes: HIV, malaria, and tuberculosis.2
Since 2002, the reduction in the number of under-five deaths as a result of these
three diseases has been 37.6%, almost twice the reduction in the total under-five
deaths.
These patterns have been running parallel to official (and unofficial) donors’
growing concern about malaria, HIV, and tuberculosis. A symptom of this fo-
cused attention was the inclusion of the fight against malaria and HIV as one of
the eight Millennium Development Goals. Also in line with this enhanced inter-
est was the creation in 2002 of the Global Fund to Fight AIDS, Tuberculosis and
Malaria (GF), or the enactment since 2003 of the U.S. President’s Emergency
Plan for AIDS Relief (PEPFAR). As a result, official development assistance
(ODA) disbursed for the purpose of fighting these three diseases increased from
less than $ 900 million in 2002 to close to $ 8 bn in 2008. For reference, dur-
ing the same time period, ODA disbursed for all health sectors increased from
almost $4.5 bn in 2002 to around $15 bn in 2008.3
Despite some criticism of the excessive emphasis on malaria and HIV,4 one
might be tempted to conclude that the focus on malaria, HIV and tuberculosis
has been appropriate, and has helped to reduce child mortality rates.
Jumping to that conclusion is, of course, unwarranted. Indeed, the causal
2 In fact, tuberculosis killed 44% more children under five in 2008, compared with 2002.
However, the tuberculosis death toll represented less than 0.5% of all under five deaths in
2002.
3An alternative estimation is offered by Pitt et al (2010), by completing data from the
CRS. According to this estimate, total health ODA increased from around $ 7.6 bn in 2003
to $ 15.6 bn in 2008, whereas health ODA directly addressed at maternal, newborn, and child
health increased from $ 2.6 bn to $ 5.4 bn over the same time span. The DAC IDA for the
sample we will use in this analysis increased from $ 2002 to $ 6.3 bn in 2008. Of this, the aid
for the purpose of fighting malaria, STD/HIV and tuberculosis represented less than a third
in 2000, about 50% in 2002, but more than 90% in 2008.
4 See for instance Liese and Schubert (2009), or England (2008).
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relationship between increased aid for these purposes and the reduction in mor-
tality attributable to the three causes cannot be concluded from the parallel
developments of aid and mortality.5 The conclusion that the choice of focus
was correct is even more problematic. This would imply establishing that ODA
targeted at malaria, HIV, and tuberculosis had a bigger impact on the reduc-
tion in mortality than ODA targeted at fighting other causes of mortality. The
goal of this paper is to investigate whether the data available offers evidence
to support these two claims. To this end, we investigate the statistical rela-
tionship between aid for different purposes and child mortality across time and
countries once endogeneity concerns have been taken into account, so that the
relationship found can indeed be considered causal.
Mortality, and child mortality in particular, is not the only indicator to mea-
sure the impact of aid on health. Nevertheless, this indicator is widely used as
the best proxy for needs and results. For instance, the MDG’s include the re-
duction of under five mortality rates as a target in itself. Mortality is easier
to measure and less subject to variation of definition than other measures of
health.6 The reduction in mortality is a common output of health interventions
that may be somewhat diverse in their immediate purposes, and so it offers
grounds for comparing performance. Finally, child mortality is arguably more
directly related to health interventions than adult mortality, and so should re-
flect the impact of those interventions more clearly. Thus, bearing in mind that
child mortality is but one of the indicators of health, we investigate whether
its reduction in developing countries is a (partial) consequence of aid for the
control of infectious diseases.
5The WHO World Malaria Report, 2010 recognizes the difficulties in establishing causality
between measured interventions and malaria outcomes, although it then takes the less-than-
satisfactory approach of considering a more or less constant health outcome as the right
counterfactual.
6For instance, malaria prevalence indexes are difficult to construct, and data on these
indexes is only available for very recent times.
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Our approach may be considered complementary to other exercises that at-
tempt to directly measure the impact of certain interventions on related health
outcomes. In most cases, these are better instruments for evaluating specific
health programmes and testing alternative interventions. However, success in
those exercises does not suffice to make a real change happen. As stressed by,
for instance, the Task Force on Child Health and Maternal Health, we need to
understand what it takes to deploy those proven interventions, an important
component of which is the absorptive capacity of recipient health systems. The
Task Force puts it nicely: "the transition from efficacy of interventions to ef-
fectiveness of delivery strategies is where we so often lose our way" (Freedman
et al., 2005). Our exercise helps measure the extent to which the current set of
interventions is attaining its goal. If real progress is being made in improving
strategies and efficiency, then real progress should also be observed in aggregate
health outcomes. Child mortality is perhaps one of the best indices of these
aggregate outcomes in recipient countries.
Our task requires the identification of an exogenous variation of ODA for the
purposes mentioned. To do that, we use a simple instrumentation strategy that
we introduced in a previous article.7 This strategy exploits country-specific time
trends in ODA in order to establish a causal relationship between ODA and child
mortality. The identification strategy is one of the main differences between our
exercise and previous ones. Other recent papers find that aid has no causal effect
on child mortality.8 There are two main differences between that literature and
this paper. First, while the previous literature uses data on aid commitments,
we focus on aid disbursements. It is well known that aid commitments do
not always translate into actual disbursements, which highlights the need to
focus on the latter in order to evaluate aid effectiveness. The second is that
7See Burguet and Soto (2011).
8Chauvet et al. (2009), Mishra and Newhouse (2009), and Wilson (2011).
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we explicitly address the endogeneity of aid to account for the "feedback" from
mortality to aid9. The estimation techniques used in the existing literature are
not appropriate if the shocks to mortality are persistent10.
We find that infectious disease aid (IDA) has a statistically significant impact
on under-five mortality over the 2000-2010 period, whereas other forms of health
aid lack significance. We estimate that at the country mean per capita aid, IDA
caused an average drop of 14 deaths per thousand under-five children born alive
over the sample period. The effect is an average drop of 33 in the under-five
mortality rate at IDA levels of 2010. For reference, the country average under-5
mortality rate in our sample for 2010 is about 54 per thousand.
When we consider the effects of the various targets of IDA, we find that
aid for malaria control, which represents about 12 per cent of total IDA in the
period, has significantly contributed to the reduction in child mortality. In fact,
this type of aid accounts for around two thirds of the reduction in the average
child mortality that can be attributed to IDA. Aid for STD/HIV control also
had a statistically significant effect on child mortality, although the per capita
dollar impact in this sector is statistically smaller than that of aid for malaria
control. Finally, aid for the control of tuberculosis and other infectious diseases
had no statistically significant impact on under-five mortality.11
Thus, the data suggest that the focus on malaria and STD/HIV in particular
may have been well founded. On the other hand, the smaller impact of aid for
STD/HIV control in comparison with the impact of aid for malaria control
may be interpreted as indication that, as some critics have suggested, there
is an overemphasis on STD/HIV control. Note that almost 80% of total IDA
disbursed in our sample period accrues to this sector.
9Deaton (2010).
10Arellano and Bond (1991) and Blundell and Bond (1998).
11We find that in Sub-Sahara Africa TB control aid has a significant effect at a 90% confi-
dence level. However non African countries, and Asia in particular, have attracted relatively
more aid for this purpose.
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We should be quick to point out that there may be reasons to expect a modest
impact on child mortality in particular during the very first years of application
of the most effective strategies to fight HIV/AIDS, even if the overall effect on
the population is sizable. Indeed, most children with HIV acquire the virus from
their mothers (MTCT) during pregnancy, delivery, or through breastfeeding.
The prevention of this MTCT requires strategies that are either unaffordable
for the population most affected or only recently available (c-section, alternative
to or prophylactic breastfeeding, etc.).12 More than in other cases, success
in this area may depend on strengthening the general health system, and in
particular maternal, neonatal and child health services.13 Progress in that area
in particular may then be expected to be slower than in the fight against HIV
in the population as a whole. Thus, perhaps by only measuring the effect of
STD/HIV control on child mortality we are underestimating the effect on total
mortality and health outcomes in general. For instance, according to Druce and
Nolan (2007), only 8% of all infants exposed to HIV in that year were receiving
antiretroviral prophylaxis, whereas for adults the figure was 28%. That said,
the data suggests the need to discuss whether the relative emphasis on each
purpose is well founded.
2 Data
We use data from the OECD’s Creditor Reporting System on aid. This data
is classified according to the purpose of aid, country of destination and the
year in which disbursements take place. The focus here is on aid to prevent
and control infectious diseases. The OECD distinguishes four different types
12See Newell et al., (2004).
13Antiretroviral therapy for pregnant women seems to reduce the risk of transmission.
However, according to the UNAIDS’ report, in 2008 only an estimated 18% of pregnant
HIV-positive women received testing in antenatal care clinics worldwide, with wide varia-
tions across countries. The report explicitly expresses to donors and countries the need for
improvement in this aspect.
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of aid in this area. These are "Malaria control", "Tuberculosis control" "STD
control including HIV/AIDS" and "Infectious disease control" (which includes
immunization, prevention and control of any infectious disease not included in
the other categories). As is well known, there has been a considerable increase
in IDA (Figure 1). Total official aid disbursements rose from about $527 million
in 2000 to more than $10.5 billion in 2010 (all figures are in constant 2010
prices; aid commitments increased from $1.8 billion to nearly $10.8 billion over
the same period). This massive increase in IDA is mainly due to a surge in aid
to fight STD/HIV, which accounts for more than 23 of total IDA in 2010.
It is important to note that the increase in IDA is not homogeneously dis-
tributed across countries. In particular, being a high mortality country does
not imply that the country receives relatively larger amounts of IDA (Figure
2; in this and following figures we represent the 30 countries with the highest
under-five mortality rates in the sample). For instance, the Central African
Republic has higher than average mortality and HIV prevalence rates but re-
ceives lower than average per capita IDA. More importantly, some countries, like
Chad, Guinea and Niger, display a fairly flat evolution of IDA over the sample
period, whereas in other countries the evolution of IDA has a markedly positive
trend. The heterogeneity in the distribution and evolution of aid also applies to
individual IDA categories. Some countries with historically high malaria death
rates like Nigeria and Sierra Leone14 have received relatively modest and con-
stant amounts of aid for malaria control, while others have benefited from large
aid increases. A similar situation occurs in the case of aid for STD/HIV control,
tuberculosis control and, to a lesser degree, other infectious disease control (fig-
ures 4 to 6, respectively). From a statistical point of view, this diversity in the
evolution of aid is important because it produces variation in the data which
can be used to identify the effect of aid on mortality. As discussed below, this
14Murray et al (2012).
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is the key for our identification strategy.
3 Methodology
To estimate the effect of aid on mortality we follow the approach implemented
in Burguet and Soto (2011). In particular, we estimate the following equation
 =  +  + −1 + X−1 +  (1)
where  is the under-five mortality rate (per thousand children born alive)15
in country  and year  ( = 2000  2010),  is the amount of aid (in 2010
dollars) divided by total population in country ,  is a set of other variables
that potentially determine mortality,  and  are country and year specific
effects, and  is a mortality shock. In the regressions that we will discuss,
 will be an aggregate of other types of aid, different from . The term 
captures common time trends in mortality across countries. We seek to obtain
reliable estimates of the coefficient . If aid effectiveness is small then  would
not be significantly different from zero.
Equation (1) implies that aid received in a given year only affects mortality
the following year. This may be unrealistic if some aid programmes (for instance,
a vaccination campaign) have long-term effects on mortality. A second concern
about the estimation of (1) refers to the potential feedback from mortality to
aid. Countries that undergo a mortality surge may attract more aid to try
to counteract the increase in mortality. This implies that a simple ordinary
least-square (OLS) regression for equation (1), would produce positively biased
estimates for the coefficient .
We address both problems with two-stage least square (2SLS) estimation.
15Mortality data is from IGME (2011)
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To do so we use two different instrumental variables16 . In most developing coun-
tries, IDA displays a positive trend over the sample period. This is the result of
the increased global awareness of the need to fight infectious diseases and not the
consequence of increases in mortality due to those diseases. For instance, recent
estimates for most developing countries find that the probability of death from
malaria was smaller in 2010 than in 2000.17 We exploit this exogenous trend in
aid to build an instrument from the predicted values of a regression of per capita
aid on a country-specific time trend. These fitted values are strongly correlated
with aid itself and thus fulfill the identification condition. We formally test the
exogeneity of the trend instrument by performing standard overidentification
restriction tests, which do not reject the exogeneity hypothesis. An important
additional feature of this instrument is that the estimated parameter  captures
the cumulative effect that aid given in the past might have on current mortality.
Thus, our concern for the potential long-term effects of aid on mortality is also
addressed by this instrumentation strategy.
In order to perform overidentification restriction tests we require a second
(exogenous) instrument. We draw on the strong negative correlation between
the size of a country and the amount of per capita aid it receives.18 The liter-
ature on aid effectiveness has used total population as an instrument for aid.19
Here we use total GDP as an instrument rather than population in order to
dissipate concerns about a potential correlation between population size and
mortality shocks. Total GDP is also significantly and negatively correlated with
per capita aid flows. Moreover there is no evidence that total GDP is correlated
with mortality shocks, which validates its use as an exogenous instrument.
16 In Burguet and Soto (2011) we provide a detailed description of the estimation technique.
17Murray et al. (2012).
18Easterly (2009).
19 See for example Boone (1996), Burnside and Dollar (2000), Hansen and Tarp (2001) and
Clemens et al. (2004).
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4 Results
We estimate the effects of IDA and other types of aid (table 1; in this and all
subsequent tables we report OLS and 2SLS estimates). That is, in (1) we let
 be total ODA net of IDA. We find that the coefficient of IDA is negative
and highly significant while the coefficient of total non-IDA is not statistically
different from zero. We repeat the exercise defining  as health aid different
from IDA and obtain the same results for IDA and again there is a lack of
significance of other health aid. As expected, point estimates from 2SLS are
larger (in absolute value) than OLS coefficients, although differences are not
statistically significant.
Next, we split IDA into four different purposes: fight against malaria, tuber-
culosis, STD/HIV, and other infectious diseases. In table 2 we report how these
four different components of IDA impact under-five mortality. In each case, we
let  in (1) be total IDA net of aid for the purpose considered. All coefficients
in the 2SLS are negative and larger in absolute value (except in the regression
for TB) than the corresponding coefficients in the OLS estimations, although
they are not statistically different in the two sets of regressions. That is an
indication that OLS coefficients suffer from an upward bias. In other words, aid
flows to high mortality countries rather than the other way round.
The most robust conclusion that we can obtain from the results reported in
table 2 is that malaria control and STD/HIV control had a statistically signifi-
cant effect in reducing child mortality. Indeed, in any grouping, the coefficients
of aid categories containing these types of aid are significant at a 99% confi-
dence level.20 Moreover, aid groupings not containing aid for malaria control or
STD/HIV control are never significant at a 90% (or higher) confidence level. All
the coefficients are negative, as we would expect, but the coefficients on "Other
20The sizes of the coefficients across regressions are coherent, taking into account the relative
sizes of the four categories of aid considered.
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infectious disease control" and "Tuberculosis control" are not statistically dif-
ferent from zero in either of the regressions.
Point estimates of the 2SLS estimations suggest that, at the average compo-
sition in the sample period, a dollar per capita IDA disbursement is generally
associated with a country average decline in under-five mortality rate by 072
(table 1, confidence interval (03 11)).21 The sample country-average IDA is
$198 per capita, which means that IDA disbursed in the period has reduced
under-five mortality by about 14 children per thousand children born alive
(06 22). In 2010, mean IDA disbursements were $464, which indicates that
later levels of IDA may contribute to an average reduction of about 34 points
in the under-five mortality rate.
The regressions by IDA components offer a consistent picture, although the
point estimates change. The most informative exercises are those presented in
columns 4 and 8, where we regress under-five mortality respectively on malaria
control and STD/HIV control using the remaining IDA as an additional co-
variate. Column 4 indicates that malaria control disbursements, which amount
to $022 on average in the sample, have reduced child mortality by almost 18
on average (09 27). On the other hand, column 8 indicates that STD/HIV
control disbursements, averaging $143 per capita in the sample, have reduced
child mortality by 06 on average (02 11).
As a robustness check, we replicate the regressions by including other con-
trols that may have some impact on under-five mortality. The results are re-
ported in table 3. Again, we estimate equation (1) using both OLS and 2SLS
regressions. This time  is a vector that also includes a measure of violent
conflict, the proportion of urban population, a measure of trade openness (ex-
ports plus imports as a share of GDP), the (log of) per capita income and
21The maximum 2SLS point estimate corresponds to the regression in column 8 in table
2, where we obtain an average effect of each per capita dollar of a 185 reduction in child
mortality.
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income growth.22 The urban population rate and violent conflict have statis-
tically significant coefficients in all regressions. Income level is significant in
some regressions, while trade openness and income growth are not statistically
different from zero. All the coefficients have the expected sign. With respect to
aid, the sizes and significance levels of the variables are virtually unaffected.23
To summarize, the evidence suggests that IDA has contributed to the re-
duction in child mortality in developing countries experienced during the 2000-
2010 period. Also, the emphasis on malaria in particular seems to have been
well founded. Indeed, in comparison with other health interventions, malaria
control seems to have had a clearly higher effect in reducing child mortality.
STD/HIV control has also had a statistically significant effect on reducing child
mortality, although the effect of a dollar per capita being spent in the average
country has had a smaller impact than a dollar being spent for malaria control.
Finally, the impact of tuberculosis control on child mortality is tenuous from a
statistical point of view.
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Figure 1: Official aid to developing countries
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Figure 3: Malaria control aid to high mortality countries
05
1
0
>
2
0
0
5
1
0
>
2
0
0
5
1
0
>
2
0
0
5
1
0
>
2
0
0
5
1
0
>
2
0
2000 2005 2010 2000 2005 2010 2000 2005 2010 2000 2005 2010 2000 2005 2010 2000 2005 2010
Angola Benin Burkina Faso Burundi Cameroon Central African Rep.
Chad Congo, Dem. Rep. Cote d'Ivoire Ethiopia Gambia Guinea
Guinea-Bissau Lesotho Liberia Malawi Mali Mauritania
Mozambique Niger Nigeria Rwanda Senegal Sierra Leone
Swaziland Tanzania Togo Uganda Zambia Zimbabwe
P
e
r
 
c
a
p
i
t
a
 
a
i
d
 
(
$
;
 
2
0
1
0
 
p
r
i
c
e
s
)
Source: Own calculation from OECD Creditor Reporting System
Figure 4: STD/HIV/AIDS control aid to high mortality countries
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Figure 5: Tuberculosis control aid to high mortality countries
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Figure 6: Other infectious disease control aid to high mortality countries
TABLE 1
Dependent variable: Under-5 mortality rate (per thousand children born alive), 2000-2010
(1) (2) (3) (4)
OLS 2SLS OLS 2SLS
Infectious disease aid (IDA) -0.516*** -0.739*** -0.478** -0.703***
(0.171) (0.181) (0.198) (0.216)
All other aid 0.00358 0.0170
(0.00549) (0.0258)
Other health aid -0.173 -0.741
(0.129) (0.494)
Observations 1,380 1,380 1,214 1,214
R-squared 0.625 0.611 0.604 0.573
Number of countries 130 130 129 129
F-test for instruments in first-stage regression . 3844 . 138.7
Hansen J test p-value . 0.259 . 0.547
Robust standard errors in parentheses
*** p<0.01, ** p<0.05, * p<0.1
Time and country effects included in all regressions
TABLE 2
Dependent variable: Under-5 mortality rate (per thousand children born alive), 2000-2010
(1) (2) (3) (4) (5) (6) (7) (8)
OLS 2SLS OLS 2SLS OLS 2SLS OLS 2SLS
Aid purpose:
Other Infectious disease control -1.281 -4.790
(1.346) (6.043)
Malaria control -3.991*** -8.141***
(1.175) (2.207)
Tuberculosis control -2.206 -1.962
(2.046) (4.838)
STD control including HIV/AIDS -0.370*** -0.440***
(0.117) (0.159)
Net IDA -0.476*** -0.690*** -0.390*** -0.510*** -0.480*** -0.706*** -3.103*** -6.702***
(0.165) (0.179) (0.112) (0.143) (0.183) (0.202) (0.796) (1.612)
Observations 1,277 1,277 1,376 1,376 1,373 1,373 1,266 1,266
R-squared 0.609 0.592 0.657 0.604 0.625 0.616 0.636 0.571
Number of countries 130 130 130 130 130 130 130 130
F-test for instruments in first-stage regression . 116.0 . 4389 . 604.4 . 885.5
Hansen J test p-value . 0.579 . 0.260 . 0.435 . 0.162
Robust standard errors in parentheses
*** p<0.01, ** p<0.05, * p<0.1
Time and country effects included in all regressions
All explanatory variables are one-year lagged
Net IDA is IDA net of the aid purpose considered
TABLE 3
Dependent variable: Under-5 mortality rate (per thousand children born alive), 2000-2010
(1) (2) (3) (4) (5) (6) (7) (8)
OLS 2SLS OLS 2SLS OLS 2SLS OLS 2SLS
Aid purpose
Other Infectious disease control 0.376 3.146
(1.118) (4.844)
Malaria control -3.686*** -8.110***
(1.145) (2.140)
Tuberculosis control -2.803 -2.189
(2.384) (5.349)
STD control including HIV/AIDS -0.418*** -0.520***
(0.155) (0.145)
Net IDA -0.530** -0.798*** -0.436*** -0.577*** -0.505** -0.765*** -2.893*** -6.352***
(0.209) (0.210) (0.145) (0.123) (0.221) (0.240) (0.834) (1.639)
Other explanatory variables:
Log(Per capita income) -6.105* -6.996** -4.648 -7.607** -2.406 -3.039 -5.538 -6.957*
(3.461) (3.232) (3.298) (3.124) (3.432) (3.597) (3.785) (3.815)
Income growth rate -1.379 -2.695 6.285 9.291* 2.464 1.873 2.394 4.846
(5.524) (5.383) (4.876) (4.869) (5.099) (5.018) (5.123) (4.919)
Trade Openess -1.256 -1.102 -2.279 -2.058 -2.592 -2.646 -3.038 -3.042
(2.186) (2.092) (2.432) (2.261) (2.613) (2.628) (2.357) (2.266)
Urbanization rate -0.868*** -0.815*** -0.861*** -0.597** -1.044*** -0.948*** -0.956*** -0.781***
(0.311) (0.294) (0.283) (0.260) (0.311) (0.298) (0.301) (0.290)
Conflict 4.860** 4.898** 4.898*** 4.151** 5.327*** 5.227*** 5.289** 4.560**
(1.990) (1.960) (1.793) (1.677) (1.949) (1.918) (2.177) (2.022)
Observations 1,188 1,188 1,280 1,280 1,280 1,280 1,174 1,174
R-squared 0.646 0.627 0.690 0.628 0.665 0.654 0.670 0.609
Number of countries 126 126 126 126 126 126 125 125
F-test for instruments in first-stage regression . 272.7 . 2073 . 236.4 . 707.0
Hansen J test p-value . 0.268 . 0.459 . 0.242 . 0.532
Robust standard errors in parentheses
*** p<0.01, ** p<0.05, * p<0.1
Time and country effects included in all regressions
All variables are one-year lagged
Net IDA is total IDA net of the aid purpose considered
